Amylin Pharmaceuticals and Takeda announced they were discontinuing development of pramlintide/metreleptin, a twice-daily injectable Phase 2 combination of the amylin analog pramlintide and the leptin analog metreleptin for obesity, after a commercial reassessment of a revised development plan and shifting obesity-field dynamics. The release keeps SYMLIN (pramlintide acetate) marketed and signals the hormonal-amylin-plus-leptin strategy that resurfaced years later in next-gen analogs.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.